CancerDrs

Ovarian Cancer clinical trials in Washington

42 actively recruiting ovarian cancer trials at 33 sites across Washington.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Network

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…

Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Sites in Washington:
  • Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
  • Overlake Medical Center — Bellevue, Washington
  • PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
  • Highline Medical Center-Main Campus — Burien, Washington
  • Providence Regional Cancer System-Centralia — Centralia, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with alkylating agents. Alkylating agents are part of s…

Sponsor: Children's Oncology Group
NCT ID: NCT06513962
Sites in Washington:
  • Seattle Children's Hospital — Seattle, Washington
  • Fred Hutchinson Cancer Center — Seattle, Washington
  • University of Washington Medical Center - Montlake — Seattle, Washington
  • Providence Sacred Heart Medical Center and Children's Hospital — Spokane, Washington
  • Madigan Army Medical Center — Tacoma, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.

Sponsor: Incyte Corporation
NCT ID: NCT07214779
Sites in Washington:
  • Virginia Mason Medical Center — Seattle, Washington
  • Fred Hutchinson Cancer Center — Seattle, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice…

Sponsor: Genelux Corporation
NCT ID: NCT05281471
Sites in Washington:
  • Providence Sacred Heart Medical Center & Children's Hospital — Spokane, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.

Sponsor: Imunon
NCT ID: NCT06915025
Sites in Washington:
  • Providence Sacred Heart Medical Center & Children's Hospital — Spokane, Washington
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Washington:
  • Swedish Cancer Institute-Edmonds — Edmonds, Washington
  • Swedish Cancer Institute-Issaquah — Issaquah, Washington
  • Providence Regional Cancer System-Lacey — Lacey, Washington
  • Valley Medical Center — Renton, Washington
  • Swedish Medical Center-First Hill — Seattle, Washington
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…

Sponsor: Genmab
NCT ID: NCT05579366
Sites in Washington:
  • Swedish Cancer Institute — Seattle, Washington
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Washington:
  • University of Washington, Fred Hutchinson Cancer Center — Seattle, Washington
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…

Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Washington:
  • University of Washington School of Medicine — Seattle, Washington
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine …

Sponsor: AbbVie
NCT ID: NCT07059845
Sites in Washington:
  • Virginia Mason Hospital and Medical Center /ID# 277259 — Seattle, Washington
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in comb…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04104776
Sites in Washington:
  • Swedish Cancer Institute — Seattle, Washington
  • Fred Hutchinson Cancer Center — Seattle, Washington
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…

Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Washington:
  • Seattle Children's Hospital — Seattle, Washington
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective th…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06787612
Sites in Washington:
  • Swedish Cancer Institute — Seattle, Washington
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

The purpose of this multicenter, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in participants with ovarian cancer and Non…

Sponsor: Tubulis GmbH
NCT ID: NCT06303505
Sites in Washington:
  • Providence Sacred Heart Medical Center — Spokane, Washington
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmaco…

Sponsor: Incyclix Bio
NCT ID: NCT05735080
Sites in Washington:
  • Northwest Medical Specialties, PLLC — Tacoma, Washington
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…

Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Washington:
  • Fred Hutchinson Cancer Center — Seattle, Washington
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both cemiplimab and fianlimab (also known as REGN3767), or * combined with ubamatamab (…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT04590326
Sites in Washington:
  • Seattle Cancer Care Alliance at South Lake Union - G3630 — Seattle, Washington
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesoth…

Sponsor: A2 Biotherapeutics Inc.
NCT ID: NCT06051695
Sites in Washington:
  • Fred Hutchinson Cancer Center — Seattle, Washington
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it…

Sponsor: Bayer
NCT ID: NCT06760819
Sites in Washington:
  • Gynecology Oncology clinic at UW Medical Center - Montlake — Seattle, Washington
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer

The purpose of this study is to evaluate the optimal dose of 2X-121 as single agent therapy at 600 mg daily (split BID 200 mg morning + 400 mg evening) compared to 800 mg daily (split BID 400 mg morning + 400 mg evening) in recurrent, adva…

Sponsor: Allarity Therapeutics
NCT ID: NCT03878849
Sites in Washington:
  • Swedish Center for Research and Innovation — Seattle, Washington
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence

This phase II trial studies how well giving the insulin-like growth factor binding protein 2 \[pUMVC3-hIGFBP-2 multi-epitope plasmid deoxyribonucleic acid (DNA) (IGFBP-2)\] vaccine after one dose of carboplatin works to stop ovarian cancer…

Sponsor: University of Washington
NCT ID: NCT07495124
Sites in Washington:
  • Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View on ClinicalTrials.gov →

Showing 25 of 42 trials with sites in Washington. See all ovarian cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-01